ArticleDiabetologia2019
Serum kidney injury molecule 1 and β
Article in Diabetologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Biomarkers Associated With Severe COVID-19 Among Populations With High Cardiometabolic Risk: A 2-Sample Mendelian Randomization Study.JAMA network open · 2023Pooled it
- Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures.Life (Basel, Switzerland) · 2026Review
- Reappraising Kidney Biopsy in Diabetic Kidney Disease: Histopathology, Clinical Course, and the Future of Precision Nephrology.Journal of clinical medicine · 2026Review
- Evaluation of cystatin C and microalbuminuria as predictive markers for hypertension-related renal complications.Hereditas · 2025Article
- Complement Proteins Identify Rapidly Progressive Diabetic Kidney Disease.Kidney international reports · 2025Article
- Article
- Metabolomics for the Identification of Biomarkers in Kidney Diseases.Nanotheranostics · 2025Review
- Steps to understanding diabetes kidney disease: a focus on metabolomics.The Korean journal of internal medicine · 2024Review
- Article
- Proteomic profiling of longitudinal changes in kidney function among middle-aged and older men and women: the KORA S4/F4/FF4 study.BMC medicine · 2023Article
- Evidence Linking Cadmium Exposure and βToxics · 2023Article
- Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study.Cardiovascular diabetology · 2023Article
- Serum beta-2 microglobulin as a predictor of nephritis, disease activity, and damage score in systemic lupus erythematosus: a cross-sectional study.Rheumatology international · 2023Article
- Diagnostic value of α1-MG and URBP in early diabetic renal impairment.Frontiers in physiology · 2023Article
- Precision Medicine in Diabetic Kidney Disease: A Narrative Review Framed by Lived Experience.Canadian journal of kidney health and disease · 2023Review
- Betanin ameliorates fipronil-induced nephrotoxicity via activation of Nrf2-HO-1/NQO-1 pathway in albino rat model.Toxicology research · 2022Article
- Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease.Diabetes/metabolism research and reviews · 2022Review
- Novel biomarkers for diabetic kidney disease.Kidney research and clinical practice · 2022Article
- Recent Progress in the Diagnosis and Management of Type 2 Diabetes Mellitus in the Era of COVID-19 and Single Cell Multi-Omics Technologies.Life (Basel, Switzerland) · 2022Review
- Associations of Plasma Biomarkers of Inflammation, Fibrosis, and Kidney Tubular Injury With Progression of Diabetic Kidney Disease: A Cohort Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 10 institutions in 4 countries.
Funding
Abstract
aims/hypothesisAs part of the Surrogate Markers for Micro- and Macrovascular Hard Endpoints for Innovative Diabetes Tools (SUMMIT) programme we previously reported that large panels of biomarkers derived from three analytical platforms maximised prediction of progression of renal decline in type 2 diabetes. Here, we hypothesised that smaller (n ≤ 5), platform-specific combinations of biomarkers selected from these larger panels might achieve similar prediction performance when tested in three additional type 2 diabetes cohorts.
methodsWe used 657 serum samples, held under differing storage conditions, from the Scania Diabetes Registry (SDR) and Genetics of Diabetes Audit and Research Tayside (GoDARTS), and a further 183 nested case-control sample set from the Collaborative Atorvastatin in Diabetes Study (CARDS). We analysed 42 biomarkers measured on the SDR and GoDARTS samples by a variety of methods including standard ELISA, multiplexed ELISA (Luminex) and mass spectrometry. The subset of 21 Luminex biomarkers was also measured on the CARDS samples. We used the event definition of loss of >20% of baseline eGFR during follow-up from a baseline eGFR of 30-75 ml min
resultsTwelve biomarkers showed significant association with eGFR decline adjusted for covariates in one or more of the sample sets when evaluated singly. Kidney injury molecule 1 (KIM-1) and β CONCLUSIONS/
interpretationSerum KIM-1 and B2M independently improve prediction of renal decline from an eGFR of 30-75 ml min
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.